Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Dhivya R SudhanLuis J SchwarzAngel L Guerrero-ZotanoLuigi FormisanoMellissa J NixonSarah CroessmannPaula I Gonzalez EricssonMelinda SandersJustin M BalkoFrancesca Avogadri-ConnorsRichard E CutlerAlshad S LalaniRichard BryceAlan AuerbachCarlos L ArteagaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These data suggest that ER blockade leads to reactivation of ERBB RTKs and thus extended ERBB blockade is necessary to achieve durable clinical outcomes in patients with ER+/HER2+ breast cancer.